The recent share sale by the CEO and the absence of insider buying over the past year may raise concerns. The low level of insider ownership compared to most companies is also somewhat worrying. Caution is advised when considering buying KalVista Pharmaceuticals stock.
The termination of the KVD824 trial may impact KalVista's financials and stock price, but the company remains focused on advancing its other drug, sebetralstat, and its oral Factor XIIa inhibitor program for HAE prophylaxis.
KalVista Pharmaceuticals股票討論區
Ph 3 readouts in Q1 2024...
$Regenxbio(RGNX.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood醫藥(IRWD.US)$ Phase 3
$阿里拉姆制藥(ALNY.US)$ Phase 3
$福泰製藥(VRTX.US)$ Phase 3
$KalVista Pharmaceuticals(KALV.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$Novocure(NVCR.US)$ Phase 3
$羅氏(ADR)(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$Applied Therapeutics(APLT.US)$ Phase 3
$阿卡迪亞(ACAD.US)$ Phase 3...
could be something brewing here
Biotech stocks catalyst in 2020
$TG Therapeutics(TGTX.US)$
$Biohaven(BHVN.US)$
$Akero Therapeutics(AKRO.US)$
$Ascendis Pharma A/S(ASND.US)$
$KALA BIO(KALA.US)$
Biotech stocks catalyst in 2020
$TG Therapeutics(TGTX.US)$
$Biohaven(BHVN.US)$
$Akero Therapeutics(AKRO.US)$
$Ascendis Pharma A/S(ASND.US)$
$KALA BIO(KALA.US)$
暫無評論